Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I would love to hear of a promising stock on the otc, pray tell!!!
RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine
Published
Feb 13, 2024 8:30am EST
Glen Rock, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that KRM-II-81, its lead GABAA receptor potentiator (GABAkine), has advanced to the next level of evaluation within the NIH HEAL Initiative® Preclinical Screening Platform for Pain (PSPP) program.
The Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, is an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management. For more information, visit: https://heal.nih.gov.
The PSPP program, part of the NIH HEAL Initiative, evaluates non-opioid assets in a battery of established preclinical pain models. The PSPP program accepts small molecules, biologics, devices, or natural products for evaluation, from researchers in academia and industry worldwide. For more information, visit: https://heal.nih.gov/research/preclinical-translational/screening-platform.
Emerging data showed that KRM-II-81 blocked pain-like behaviors in rats at doses with minimal or no detectable side effects. These observations were made with both male and female rats in two measures each, in models of post-incision pain and spinal nerve ligation-induced persistent neuropathic pain. These research findings support prior observations by our and other laboratories that KRM-II-81 is effective in relieving acute, chronic, and neuropathic pain in a number of models without tolerance development or sedation. These data trigger the advancement of KRM-II-81 within the NIH PSPP program where additional disease-specific pain models will be evaluated.
Dr. Jeffrey M. Witkin, a Senior Research Fellow with the Company said that “we are excited to see the robust anti-pain efficacy of KRM-II-81, knowing the urgent need for non-opioid pain therapeutics. We continue to be impressed by the comparative ‘therapeutic index’ of this compound that we had predicted from earlier research.”
Dr. Lippa added, “We are all very excited about developing KRM-II-81 and expanding the IND enabling studies so as to begin human studies. Pending clinical validation, we believe that KRM-II-81 has the potential to represent a breakthrough medication for pain, epilepsy, and other neuropsychiatric disorders.”
The RespireRx team is led by Dr. Arnold Lippa, RespireRx Executive Chairman, Interim Chief Executive Officer, Interim President and Chief Scientific Officer along with RespireRx Senior Research Fellows, Drs. Jeffrey M. Witkin and Rok Cerne and collaborator, Dr. James M. Cook, in addition to their academic affiliations at Ascension St. Vincent and Indiana University/Purdue University and the University of Wisconsin-Milwaukee, respectively. The team has extensive expertise in drug discovery and development including the development of novel analgesic drugs and an extensive publication record with a combined total of over 1,000 scientific publications. The team has already profiled the activity of KRM-II-81 in a broad range of preclinical studies where it has displayed a high degree of analgesic activity and is excited at the prospect of advancing the Company’s lead GABAkine toward clinical development. In cellular studies, KRM-II-81 preferentially bound to specific subtypes of GABAA receptors and boosted the ability of GABA to inhibit pain sensory neurons in the spinal dorsal root ganglia. In intact animal models of acute and chronic pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression, or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
Unrelated to the NINDS project, KRM-II-81 has also shown very promising results in multiple animal models of treatment resistant epilepsy and in human translational studies where it reduced epileptiform electrical signaling in brain tissue removed from treatment resistant epileptic patients who underwent surgery.
About RespireRx Group
RespireRx Pharmaceuticals Inc. and its subsidiaries and business units (“RespireRx Group”) are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors.
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
EndeavourRx: Neuromodulators
GABAkines. Under a License Agreement with the University of Wisconsin-Milwaukee Research Foundation, Inc. (“UWMRF”) and on behalf of its EndeavourRx business unit, RespireRx has in-licensed rights to certain selectively acting GABAkines because of their ability to selectively amplify inhibitory neurotransmission at a highly specific, subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx currently is focusing on developing KRM-II-81 for the treatment of epilepsy and pain.
KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant animal models. Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy as a result of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment-resistant epileptic patients who underwent surgery.
In addition, KRM-II-81 has displayed a high degree of analgesic activity in a broad range of preclinical studies. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
AMPAkines. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, RespireRx has developed a family of novel, low impact AMPAkines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. Our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
AMPAkines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adult patients with ADHD. Statistically significant therapeutic effects were observed within one week. We believe AMPAkines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulants, such as Straterra® (atomoxetine), and without the drawbacks of amphetamine-type stimulants.
In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, Dr. David Fuller (University of Florida), a long-time RespireRx collaborator, has demonstrated the ability of CX1739 and CX717, RespireRx’s lead AMPAkines, to improve motor nerve activity and muscle function in a number of animal models of spinal cord injury (SCI).
ResolutionRx: Pharmaceutical Cannabinoids.
ResolutionRx Ltd (Australian Company Number a/k/a ACN 664 925 651) was formed in Australia on January 11, 2023 by RespireRx as an unlisted public company. RespireRx has contributed by sublicense and license with ResolutionRx, its sleep apnea drug development program subject to certain liabilities. ResolutionRx will now engage in the research and development (“R&D”) associated with that program, initially for the development of a new formulation of dronabinol for use in a Phase 3 clinical trial and the filing of regulatory approval for the treatment of obstructive sleep apnea (“OSA”). The current total budget for that program over the next several years is approximately US$16.5 million, most, but not all of which is expected to be eligible for the Australian R&D Tax Incentive (“RDTI”). Dronabinol, an endocannabinoid receptor agonist, has already demonstrated significant improvement in the symptoms of OSA in two Phase 2 clinical trials. OSA is a serious respiratory disorder that impacts an estimated 90 million people in the United States, Australia, the United Kingdom and Germany and that has been linked to increased risk for hypertension, heart failure, depression, and diabetes. There are no approved drug treatments for OSA.
Because dronabinol is already FDA approved for the treatment of AIDS related anorexia and chemotherapy induced nausea and vomiting, RespireRx and ResolutionRx further believe that its repurposing strategy would only require, in the United States, approval by the FDA of a 505(b)(2) new drug application (“NDA”), an efficient regulatory pathway that allows the use of publicly available data.
Additional information about RespireRx and the matters discussed herein can be obtained on the RespireRx website at www.RespireRx.com or RespireRx’s filings with the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov. Additional information about ResolutionRx and the matters discussed herein can be obtained on the ResolutionRx website at https://www.resolutionrx.com.au.
Not a Securities Offering or Solicitation
This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sales of securities in any jurisdiction in which such offer, solicitation or sale of securities would be unlawful before registration or qualification under the laws of such jurisdiction.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Company intends that such forward-looking statements be subject to the safe harbor created thereby. These might include statements regarding the Company’s future plans, targets, estimates, assumptions, financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about research and development efforts, including, but not limited to, preclinical and clinical research design, execution, timing, costs and results, future product demand, supply, manufacturing, costs, marketing and pricing factors.
In some cases, forward-looking statements may be identified by words including “assumes,” “could,” “ongoing,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” “anticipates,” “believes,” “intends,” “estimates,” “expects,” “plans,” “contemplates,” “targets,” “continues,” “budgets,” “may,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words, and such statements may include, but are not limited to, statements regarding (i) future research plans, expenditures and results, (ii) potential collaborative arrangements, (iii) the potential utility of the Company’s product candidates, (iv) reorganization plans, and (v) the need for, and availability of, additional financing. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainties and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release.
These factors include but are not limited to, regulatory policies or changes thereto, available cash, research and development results, issuance of patents, competition from other similar businesses, interest of third parties in collaborations with us, and market and general economic factors, and other risk factors disclosed in “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the SEC on April 17, 2023 (the “2022 Form 10-K”).
You should read these risk factors and the other cautionary statements made in the Company’s filings as being applicable to all related forward-looking statements wherever they appear in this press release. We cannot assure you that the forward-looking statements in this press release will prove to be accurate and therefore current and prospective investors, as well as current and potential collaborators and other current and potential stakeholders, are encouraged not to place undue reliance on forward-looking statements. You should read this press release completely. Other than as required by law, we undertake no obligation to update or revise these forward-looking statements, even though our situation may change in the future.
We caution current and prospective investors, as well as current and potential collaborators and other current and potential stakeholders, not to place undue reliance on any forward-looking statement that speaks only as of the date made and to recognize that forward-looking statements are predictions of future results, which may not occur as anticipated. Actual results could differ materially from those anticipated in the forward-looking statements and from historical results, due to the risks and uncertainties described in the 2022 Form 10-K, in our quarterly reports on Form 10-Q, in our Current Reports on Form 8-K, and other reports that we file with or furnish to the SEC and in this press release, as well as others that we may consider immaterial or do not anticipate at this time. These forward-looking statements are based on assumptions regarding the Company’s business and technology, which involve judgments with respect to, among other things, future scientific, economic, regulatory and competitive conditions, collaborations with third parties, and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. Our expectations reflected in our forward-looking statements can be affected by inaccurate assumptions that we might make or by known or unknown risks and uncertainties, including those described in the 2022 Form 10-K, in our quarterly reports on Form 10-Q, in our Current Reports on Form 8-K, and other reports that we file with or furnish to the SEC and in this press release. These risks and uncertainties are not exclusive and further information concerning us and our business, including factors that potentially could materially affect our financial results or condition, may emerge from time to time. For more information about the risks and uncertainties the Company faces, see “Item 1A. Risk Factors” in our 2022 Form 10-K. Forward-looking statements speak only as of the date they are made. The Company does not undertake and specifically declines any obligation to update any forward-looking statements or to publicly announce the results of any revisions to any statements to reflect new information or future events or developments. We advise current and prospective investors, as well as current and potential collaborators and other current and potential stakeholders, to consult any further disclosures we may make on related subjects in our annual reports on Form 10-K and other reports that we file with or furnish to the SEC including but not limited to our most recent Form 10-Q as of September 30, 2023 filed with the SEC on November 17, 2023.
Company Contact:
Jeff Margolis
RespireRx Pharmaceuticals Inc. 126 Valley Road, Suite CGlen Rock, NJ 07452Senior Vice President, Chief Financial Officer, Treasurer and Secretary Telephone: 917-834-7206Email: jmargolis@respirerx.com www.respirerx.com
optimism at its finest lol. if you own no shares, why the concern?
very intrigueing, they added shares bc the purchaser knew the value will increase once significant trials have been completed. this company is way undervalued. big players in the know have loaded the boat bc they are aware of the exponential increase in bound.
GLTA longs who stayed on the bull during this rodeo!!!
how much are you being paid to "scare" shareholders out of their shares?
The OTC Markets has identified specific circumstances in which a Caveat Emptor designation is assigned. Once assigned, more often than not, it is not removed. The circumstances are set forth below.
Promotion/Spam Without Adequate Current Information
The security is being promoted to the public, but adequate current information about the company has not been made available to the public.
Investigation of Fraud or Other Criminal Activities
OTC Markets Group becomes aware of an investigation of fraudulent or other criminal activity involving the company, its securities, or insiders.
Suspension/Halt
A regulatory authority or an exchange has halted or suspended trading for public interest concerns (i.e., not a news or earnings halt).
Undisclosed Corporate Actions
The security or company is the subject of a corporate action, such as a reverse merger, stock split, or name change, without adequate current information being publicly available.
Unsolicited Quotes
The security has only been quoted on an unsolicited basis since it entered the public markets, and the company has not made adequate current information available to the public.
Other Public Interest Concern
OTC Markets Group has determined that there is a public interest concern regarding security. Such concerns may include but are not limited to promotion, spam, or disruptive corporate actions even when adequate current information is available.
Agree!! just a matter of time to weather the storm, Absolutely Nothing has changed in regards to their pipeline!!! DoD still in affect!!! I am so glad that i bought before the door closed on this one!!! Hold for the Gold!!!
This Stock will change lives in more ways than one, ignore the naysayers. why would they even post here if they hold no position? paid opposition!!!
nice paint job 1st thing in the morning. 4k shares. ha!!
You can't buy RSPI anylonger, moot point 😀😀😀
that's SUPER funny, Haaa haaa 😐
: /
What if they get bought out for $6.27?
This is an Investment. that means you have to trust the plan, the pipeline, the Ceo, the entity who invested 100k of his own $, And you need to be patient, these things take time. but at the end of the day, you bought shares in a company that you believed has something of value to offer in its pipeline. DoD forked over 1.8 mil in grant $ because they obviously see a potential. ignore the gnats, they are small minded, think large, This is an up and coming BioPharma Company, when it validates what it has, people will kick themselves for listening to the naysayers and bailing for chump change!!! Those who stood strong, will reap the rewards of their Risk! GLTA
Maybe management decided that with the economy guru's and echoe chambers predicting a market crash, that the Expert Markets are a safe place to be while the dust settles, knowing their incredible pipeline and value that each drug holds, they did not want to give control over to the market manipulators.
Trade
Corporate Finance
M&A
How Does Privatization Affect a Company's Shareholders?
By
Caleb Silver
Updated August 28, 2023
Reviewed by
David Kindness
Fact checked by
Amanda Jackson
A private company typically goes public by conducting an initial public offering (IPO) for its shares. However, the reverse may also occur. A public company can transition to private ownership when a buyer acquires the majority of it shares. Shareholders have to agree to the sale. Those that do typically sell their shares at a premium over the current market price as compensation for giving up ownership in the company.
This public-to-private transaction results in the de-listing of the company's shares from a public stock exchange. Shares are no longer available to the public-at-large. While companies may be privatized for a number of reasons, this event often occurs when a company is substantially undervalued in the public market.
Key Takeaways
In a public-to-private deal, shareholders approve an offer from investors for their shares.
Investors offer a premium above the current market price as inducement to shareholders to give up ownership in the company.
Once private, a company's shares can no longer be traded publicly because the company is de-listed from the public exchange on which its shares once traded.
Going private is an easier process than going public due to fewer steps and regulatory hurdles.
Typically, a company seen as undervalued in the market will opt to go private, although there can be other reasons such an action is taken.
What Is Privatization?
The term privatization refers to the action of changing a publicly owned company into a privately held company. Public companies are listed on major stock exchanges. Their stock is traded publicly and can be bought and sold by any investor.
A company that goes from public to private is de-listed from the public exchange on which its shares traded. It still may issue stock but its shares will no longer be available to the public.
In addition, privatization means that a company will no longer be answerable to public shareholders or regulated as closely by the government.
How Does Privatization Work?
Taking a public company private is relatively straightforward and typically involves fewer regulatory hurdles than private-to-public transitions.
A private group will tender an offer for a company's shares and stipulate the price it is willing to pay. Typically, it's a premium over the current market price. If a majority of voting shareholders accept, the bidder pays the consenting shareholders the purchase price for every share they own.
For example, if a shareholder owns 100 shares and the buyer offers $26 per share, the shareholder receives $2,600 for relinquishing their position and ownership in the company. This situation often favors shareholders due to the aforementioned premium.
Many famous public companies have gone private and de-listed their shares from a major stock exchange. They include Dell, Panera Bread, Hilton Worldwide Holdings, H.J. Heinz, and Burger King. Some companies go private, only to return to the market as public companies with another IPO.
Privatization can be a nice boon to current public shareholders, as the investors taking the firm private will typically offer a premium over the share price's current market value.
Interest in Privatization
In some cases, the leadership of a public company will proactively attempt to take a company private. Tesla (TSLA) is one example of a company that flirted with the possibility. Ultimately, it remained public. On August 7, 2018, founder and CEO Elon Musk tweeted he was considering taking TSLA private and had secured funding at $420 per share.1
After his announcement, Tesla closed up 6.42% and trading was halted following the ensuing news frenzy. The Securities and Exchange Commission (SEC) filed a civil complaint against Musk.2 The unabashed CEO justified his intentions with the following message:
As a public company, we are subject to wild swings in our stock price that can be a major distraction for everyone working at Tesla, all of whom are shareholders. Being public also subjects us to the quarterly earnings cycle that puts enormous pressure on Tesla to make decisions that may be right for a given quarter, but not necessarily right for the long term.3
Contingency Plan
In a public to private deal, the premium that investors are willing to offer shareholders for their shares is usually contingent on the investors buying a certain number of those shares (normally, an amount that gives them control of the company). If that condition isn't met, the offer is withdrawn.
What Happens to Shares When a Company Goes Private?
When a publicly traded company becomes a privately held company, the public company's shares are purchased at a premium by the investors buying the company. The company is delisted from the stock exchange where its shares formerly traded. Shares now can no longer be traded publicly.
What Happens to Shareholders When a Company Goes Private?
Shareholders agree to accept the offer to be bought out by investors. They give up ownership in the company in exchange for a premium price for each share that they own. They can no longer buy shares in the company through a broker.
What Happens to Private Shares When a Company Goes Public?
When a private company goes public, for instance, through an initial public offering (IPO), private shares owned before the IPO may gain in value. However, they usually cannot be sold for a specific amount of time, starting on the day of the IPO. This period is known as the lockup period and may last 180 days.4
The Bottom Line
Shareholders can make out well financially when a public company goes private. In 2005, Toys "R" Us famously went private when private equity groups paid $26.75 per share to the company's shareholders.5 This price was more than double the stock's $12.02 closing price on the New York Stock Exchange in January 2004.6
So, while they may no longer have ownership in a company that goes private, shareholders are often well-compensated for relinquishing their shares.
Article Sources
Related Articles
?
Pro Forma: What It Means and How to Create Pro Forma Financial Statements
?
How Company Stocks Move During an Acquisition
?
Tender in Finance: Definition, How It Works, and Example
?
Acquisition: Meaning, Types, and Examples
?
Merger: Definition, How It Works With Types and Examples
?
Enterprise Value vs. Equity Value: What's the Difference?
Related Terms
Pro Forma: What It Means and How to Create Pro Forma Financial Statements
The Latin term pro forma, which translates to “as a matter of form," is a method of calculating financial results using certain projections or presumptions.
more
Tender in Finance: Definition, How It Works, and Example
A tender is an invitation for a company to bid on a project. In investing, a tender offer is used in stock buybacks and in response to a takeover.
more
Acquisition: Meaning, Types, and Examples
An acquisition is a corporate action in which one company purchases most or all of another company’s shares to gain control of that company.
more
Merger: Definition, How It Works With Types and Examples
A merger is an agreement that unites two existing companies into one new company. Learn here why it happens and the different types of mergers.
more
Leveraged Buyout (LBO): Definition, How It Works, and Examples
A leveraged buyout (LBO) is the acquisition of one company by another using a significant amount of borrowed money or debt to meet the cost of acquisition.
more
What Is a Private Company?
A private company is held under private ownership with shares not traded publicly
News
Privacy Policy
Contact Us
Careers
Investopedia is part of the Dotdash Meredith publishing family.
Ad
?
i guess tomorrow we find out, duped or Genius
RespireRX Pharmaceuticals chief financial officer Jeff Margolis joins Proactive's Natalie Stoberman with the news that subsidiary ResolutionRX has announced a services agreement with Australian contract research organization (CRO) iNGENu.
Margolis said iNGENu will act as a full-service CRO in support of ResolutionRx’s research and development program, which is developing a proprietary formulation of dronabinol for the treatment of obstructive sleep apnea and anorexia.
older but what has changed?
This thing has got Huge potential, it has got to be close to taking off! just waiting on the prototype and this breakthrough technology will change the world!!
so are you in UK or Malta, asking for a friend
Stock Bashing (Poop and Scoop) ✔
This often happens online where “bashers” will attack a company in hopes of the price dropping and being able to scare investors out of their assets. This is when the bashers can swoop in and purchase the asset they are looking for at a discount and turn around and sell those when the price rebounds. This after people inevitably uncover that the claims were fictitious.
Conclusion 🏁
Market manipulation may seem like it’s old as markets themselves. And it probably is. What’s important is that you keep yourself safe from the tactics and know the signs before you enter into a trade that may seem like a once in a lifetime deal. In reality, it may be some scammer just trying to take your money.
Market manipulators employ a variety of tactics, from adjusting the volume, to making it seem like the price is going to rocket, to even just adjusting the end of the day trading trends. All of these are designed to fool other traders, and even though some of the activity is technically illegal, it doesn’t mean that it’s going to go away.
So remember to be on the lookout, check where company news is coming from, try to corroborate material with other outlets, and trust your gut, as they say, if something is too good to be true, it probably is.
like a game of "Limbo" how low can you go!!! either this is organically getting crushed by folks that are buying into the fud, or it is a carefully calculated scheme to scare folks out of their shares because the end game is going to be Amazing. i am not sure, but i will go down with the ship in hopes of the Rise of the Pheonix!!!
this play seems to be mms and shorts playing on the filings, as far as the company goes, what has really changed? still have dod funding. i will go down with the ship. i am not selling, if it crashes and burns, i will have a tax loss come jan
if that happens what becomes of the value in the shares held in rspi? do shareholders who held all their shares and went down with the ship ever get credit for those shares in the subsiderary?
was yesterday's action dilution?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 2, 2024
RESPIRERX PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
Delaware 1-16467 33-0303583
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S Employer
Identification No.)
126 Valley Road, Suite C
Glen Rock, New Jersey
07452(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (917) 834-7206
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
?Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ?Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ?Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ?Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registeredN/A N/A N/A
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ?
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ?
Item 1.01 Entry into a Material Definitive Agreement.
On July 2, 2024, RespireRx Pharmaceuticals Inc. (the “Company” or “RespireRx”) entered into an NIH Service Agreement 1 (“Agreement 1”) and an NIH Service Agreement 2 (“Agreement 2”) with Alien Technology Transfer India Private Limited (“ATT India”), a company incorporated in India and with Alien Technology Transfer USA Inc. (“ATT US”), a company incorporated in the United States with offices in Texas, respectively.
Both Agreement 1 and Agreement 2 relate to the Company’s EndeavourRx’s GABAkines program.
Pursuant to Agreement 1 ATT India will provide certain services, with respect to the possible identification of and application to the most appropriate funding institutes or centers within the NIH and identification of possible SBIR/STTR targeted solicitations. These would be grant applications.
The services are to be provided in various phases, identified as Phase 0, Phase I, Phase 00 and Phase II.
Fees payable by RespireRx are success based except in cases of early termination. Success fees generally range from 10% down to 7% of the award amount. In addition, there are support fees of $8,000.00 for Phase I and $15,0000.00 for Phase II invoiced after the Company enters into a grant agreement with the federal agency regarding Phase I/Phase II.
Pursuant to Agreement 2 ATT US will provide certain services referred to as TABA services and will be performed only if the Company enters into a grant agreement with a federal agency regarding Discretionary Technical and Business Assistance (“TABA”) during Phase I and Phase II. These services may include regulatory affairs consulting, or an IP (intellectual property) package. Accounting services will be performed if RespireRx successfully accesses Phase I and/or Phase II and receives payments by the relevant federal agency in accordance with the grant agreement. Such accounting services would include grant accounting compliance training and other services. Fees for such services are separate from and in addition to the success fees associated with Agreement 1. The TABA fees are $6,500.000 for Phase I and $50,000.00 for Phase II and are to be invoiced after the Company requests the first payment regarding the TABA during Phase I/II from the federal agency. Other services range from $1,760.00 to $2,400.00 per month for Phase I and $2,400.00 to $3,200.00 per month for Phase II.
The above is a summary of what the Company believes are key the provisions of Agreement 1 and Agreement 2. A copy of the entirety of each is filed as Exhibits 10.1-10.2 to this Current Report on Form 8-K. The above summary is qualified in its entirety by this Current Report on Form 8-K including the copy of Agreement 1 between the Company and ATT India and between the Company and ATT US, each dated July 2, 2024 and filed as Exhibits 10.1-10.2 to such report.
Item 8.01. Other Events.
On July 2, 2024, the OTC Markets Group posted a notice of the commencement of a 15 calendar grace period.
The notice reads as follows:
“This security has entered a 15 calendar day Grace Period because OTC Markets Group is unable to confirm that the issuer’s disclosure is current and publicly available under Rule 15c2-11. It will be downgraded to the Expert Market at the end of this Grace Period unless OTC Markets Group determines another exception under Rule 15c2-11 applies, such as the Large Company/ADTV exception.”
At this time, the Company believes that it is unlikely that it will be able to make the required filings within the grace period and anticipates that trading will be restricted to the expert market at the expiration the grace period. To cure the deficiency, the Company is in the process of attempting to raise funds of which no assurance can be provided. RespireRx has also contacted the OTC Markets Group.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
A list of exhibits that are filed as part of this report is set forth in the Exhibit Index, which follows, and is incorporated herein by reference.
EXHIBIT INDEX
Exhibit Number Exhibit Description10.1* RespireRx - Alien Technology Transfer India Private Limited Agreement dated July 2, 202410.2* RespireRx - Alien Technology Transfer USA Inc. Agreement dated July 2, 2024104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
* Filed herewith.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 8, 2024RESPIRERX PHARMACEUTICALS INC. (Registrant) By:/s/ Jeff E. Margolis Jeff E. Margolis SVP, CFO, Secretary and Treasurer
ATTACHMENTS / EXHIBITS
ex10-1.htm
ex10-2.htm
XBRL SCHEMA FILE
XBRL LABEL FILE
XBRL PRESENTATION FILE
IDEA: R1.htm
IDEA: Financial_Report.xlsx
IDEA: FilingSummary.xml
IDEA: MetaLinks.json
IDEA: form8-k_htm.xml
RespireRx Pharmaceuticals Inc (RSPI) $0.00 0.00 (0.00%) as of 4:30 Tue 1/5
?
Download
Exchange: American Stock Exchange Security Type: Common Shares Out: 2,587,000 Market Cap: 7.50(K) Last Volume: 19,638 Avg Vol: 19,585 52 Week Range: $0.0029 - $0.0029 Level I Sector: Health Care Level II Sector: Drugs Level III Sector: Drug Manufacturers - Other
Member Indexes:
AMEX COMPOSITE
Rankings:
Insider 3 Months : -Insider 6 Months : -Insider 3/6 Months : - Guru Rank Number : -Guru Rank Value : -Guru Occurances : - ?
6 Months 1 Year 2 Year Company Profile RespireRx Pharmaceuticals is developing treatment options including obstructive sleep apnea, attention deficit hyperactivity disorder and recovery from spinal cord injury, as well as certain neurological orphan diseases such as Fragile X Syndrome. Co. is also developing a pipeline of drug products based on its patent portfolios across two drug platforms: cannabinoids, which include dronabinol; and neuromodulators, which include ampakines, proprietary compounds that positively modulate alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate-type glutamate receptors to promote neuronal function and positive allosteric modulators of the gamma-amino-butyric acid type A receptors.
?
?
?
?
?
Summary (Direct Transactions Only) ?3 Months6 Months12 Months24 MonthsTotal Shares Bought0000Total Buy Value$0$0$0$0Total People Bought0000Total Buy Transactions0000Total Shares Sold0000Total Sell Value$0$0$0$0Total People Sold0000Total Sell Transactions0000End Date2024-03-212023-12-192023-06-202022-06-20
Adjust Filter Settings
Records found: 22
Page 1 of 1 Filer's NameRelation TitleOff-Dir-10%Tran. DateForm ActionPriceMkt ValueD/IShares HoldingsRank
? 3m +/-? Form? ? Margolis Jeff EliotSVP, CFO, Secrety & Treasurer • • • 2020-09-304A$0.00$0I/I101,905,3825,142,351 -
?
? ? Jones Timothy L.CEO and President • • – 2020-09-304A$0.00$0D/D4,409,0634,409,063 -
?
? ? Margolis Jeff EliotSVP, CFO, Secretary & Teasurer • • • 2020-03-224GA$0.00$0I/I4,500,000125,207 -
?
? ? Margolis Jeff EliotSVP, CFO, Secretary & Teasurer • • • 2020-03-224GD$0.00$0D/D4,500,0000 -
?
? ? Margolis Jeff EliotSVP, CFO, Secretary & Teasurer • • • 2020-03-224A$0.00$0D/D4,500,0004,500,000 -
?
? ? Lippa ArnoldExec. Chairman, CEO, CSO • • – 2020-03-224GD$0.00$0D/D4,500,000598 -
?
? ? Lippa ArnoldExec. Chairman, CEO, CSO • • – 2020-03-224A$0.00$0D/D4,500,0004,500,598 -
?
? ? Lippa ArnoldExec Chairman, CSO • • – 2018-09-124GD$0.00$0D/D47,6200 -
?
? ? Lippa ArnoldExec Chairman, CSO • • – 2018-09-124B$0.00$0D/D47,62047,6202.73 -
?
? ? Manuso James S JPresident and CEO • • – 2017-09-134B$0.00$0D/D1,09774,2522.73 -
?
? ? Margolis Jeff EliotVP, Treasurer & Secretary • • – 2016-07-154GA$0.00$0I/I15,134,9444,000,000 -
?
? ? Margolis Jeff EliotVP, Treasurer & Secretary • • – 2016-07-154GD$0.00$0I/I5,000,0000 -
?
? ? Margolis Jeff EliotVP, Treasurer & Secretary • • – 2016-07-154GD$0.00$0D/D10,134,9440 -
?
? ? Margolis Jeff EliotVP, Treasurer & Secretary • • – 2016-06-164A$0.00$0I/I5,000,0005,000,000 -
?
? ? Margolis Jeff EliotVP, Treasurer & Secretary • • – 2016-06-164D$0.00$0D/D(5,000,000)10,134,944 -
?
? ? Manuso James S JPreident & CEO • • – 2016-04-074A$0.00$0D/D11,887,77923,775,558 -
?
? ? Margolis Jeff EliotVP, Treasurer & Secretary • • – 2015-09-144S$0.00$0D/D(483,872)15,134,944 -
?
? ? Margolis Jeff EliotVP, Treasurer & Secretary • • – 2015-09-144OE$0.00$0D/D507,37415,618,816 -
?
? ? Manuso James S JPresident and CEO • • • 2015-08-284B$0.00$0D/D11,887,77911,887,7793.15 -
?
? ? Purcell Richard David Jr.SVP - Research and Development • – – 2014-10-154A$0.00$0D/D2,000,0002,000,000 -
?
? ? Macfarlane KatieDirector – • – 2014-09-034A$0.00$0D/D2,000,0002,000,000 -
?
? ? Sapirstein JamesDirector – • – 2014-09-034A$0.00$0D/D2,000,0002,000,000 -
?
what if those shares were sold to open a short position? how would we know?
that is what i was thinking as well. High Speed internet is a Huge difference, if this company can pull this off, it is a massive Game changer!! sky is the limit, no pun intended!! $$$$$$$$ glta
oops i meant the T not the p
h ttps://www.tiktok.com/t/ZTN1Y58cA/
copy and bring the H next to the P
Could this Be DLOC's Satenna???
yes, really sucks, Schwab down too!!!
what is the signjficance of virt on bid, please explain if on bid or ask, i am clueless lol tia
Anthony Fauci telling the house oversight comittee about a monoclonal antibody he patented 27 years ago, then 25 years ago for diagnostics... at the 3min mark it starts .i am certain he attempted to claim the rights to the patent on clone3. but lost in court. someone please post the file if you have it
h ttps://youtu.be/K-O-QtDEwyU?feature=shared
if you want to post videos without them disapearing, put a space after the h in http,then copy the link and paste, then join them together
when it hits $5 Dollars and the institutional investors like the Baker Brothers start buying shares, this mustard seed will grow into a Big Big Tree
Homie!! haaa haaa, you from the 209 too lol
it's too bad that BP decided to destroy this stock like they did to Stanislaus Bryzinsky's company. how did you get sub-contacted for the basher position?
it is called Censorship, i read the filings with my own two eyes a few years back, otherwise i would not have mentioned it., now when i do a search, it magically vanished from the internet. not surprising. BP has a lot of big influence and can make things disappear, especially when the biotech threatens their massive profits.
it is just part of the playbook.
then you come along as the Gaslighter lol
asked "Chat GPT" aka Chat-zero the following:
Guest:
elaborate on the most recent updates on the uses of Clone3 monoclonal antibodies as it relates to pharmaceutical companies
Zero AI:
LATEST UPDATES ON THE APPLICATIONS OF CLONE3 MONOCLONAL ANTIBODIES IN THE PHARMACEUTICAL INDUSTRY
The utilization of Clone3 monoclonal antibodies in the pharmaceutical sector has witnessed significant advancements in recent times, with pharmaceutical companies exploring diverse applications to enhance drug development and treatment modalities. These antibodies, produced from a single parent cell, offer targeted therapy options and have shown promising results in various medical fields.
One of the key updates in the use of Clone3 monoclonal antibodies by pharmaceutical companies is their role in precision medicine. By specifically targeting antigens associated with certain diseases, these antibodies allow for personalized treatment approaches tailored to individual patients. This precision targeting minimizes side effects and maximizes therapeutic efficacy.
Moreover, pharmaceutical companies are increasingly incorporating Clone3 monoclonal antibodies in the development of innovative immunotherapies. These antibodies can modulate the immune response, making them valuable assets in treating autoimmune disorders, cancer, and infectious diseases. The ability of Clone3 monoclonal antibodies to bind selectively to disease-specific markers enhances their therapeutic potential in precision medicine.
Furthermore, recent updates highlight the use of Clone3 monoclonal antibodies in biotherapeutics, including antibody-drug conjugates (ADCs) and bispecific antibodies. These novel formulations combine the targeting capabilities of Clone3 antibodies with potent cytotoxic agents, leading to enhanced treatment outcomes in cancer therapy.
In conclusion, the evolving applications of Clone3 monoclonal antibodies in the pharmaceutical industry underscore their versatility and efficacy in addressing complex medical challenges. Pharmaceutical companies continue to leverage these antibodies to drive innovation and improve patient outcomes across diverse therapeutic areas.
ENABLING HIGH-SPEED INTERNET CONNECTION VIA SATELLITES WITH "SATENNA" FROM DIGITAL LOCATION SERVICES INC.
Digital Location Services Inc. introduces "Satenna," a groundbreaking technology designed to facilitate high-speed internet connectivity between cell phones and low Earth orbiting satellites. This innovative solution aims to revolutionize communication by providing seamless and reliable internet access even in remote or underserved areas.
"Satenna" operates by establishing a direct link between cell phones and the low Earth orbiting satellites, bypassing traditional ground-based infrastructure. This direct connection enhances speed and efficiency, enabling users to experience faster data transmission and reduced latency.
The technology behind "Satenna" leverages advanced signal processing algorithms and beamforming techniques to optimize signal strength and reliability. By dynamically adjusting signal frequencies and angles, "Satenna" ensures a stable and uninterrupted connection regardless of the user's location or movement.
Furthermore, "Satenna" incorporates cutting-edge encryption protocols to safeguard data privacy and security during transmission. This feature enhances user confidence in the system's integrity and protects sensitive information from potential cyber threats.
Overall, "Satenna" represents a significant advancement in satellite communication technology, offering a reliable and high-speed internet connection to users worldwide. Its seamless integration with cell phones and low Earth orbiting satellites positions it as a game-changer in the realm of global connectivity.
it is true, i believe that it was in 1998
Dip and Rip ......hmmmmm... we Shall See
somethin's a brewin...... shorts covering or new short positions